Qi-Dong You

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6504691/publications.pdf

Version: 2024-02-01

227 papers	7,679 citations	50276 46 h-index	79698 73 g-index
232 all docs	232 docs citations	232 times ranked	8181 citing authors

#	Article	IF	Citations
1	Targeting the HSP90â€“CDC37â€“kinase chaperone cycle: A promising therapeutic strategy for cancer. Medicinal Research Reviews, 2022, 42, 156-182.	10.5	32
2	Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope. Acta Pharmaceutica Sinica B, 2022, 12, 2990-3005.	12.0	16
3	Methods for the Discovery and Identification of Small Molecules Targeting Oxidative Stress-Related Proteinâ€“Protein Interactions: An Update. Antioxidants, 2022, 11, 619.	5.1	6
4	Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome. Journal of Medicinal Chemistry, 2022, 65, 5029-5043.	6.4	7
5	Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis. European Journal of Medicinal Chemistry, 2022, 238, 114423.	5.5	6
6	Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2022, 65, 8065-8090.	6.4	15
7	Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors. Journal of Medicinal Chemistry, 2022, 65, 8144-8168.	6.4	7
8	Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors. Journal of Medicinal Chemistry, 2022, 65, 8091-8112.	6.4	25
9	Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core. European Journal of Medicinal Chemistry, 2021, 210, 112959.	5.5	8
10	Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020). Expert Opinion on Therapeutic Patents, 2021, 31, 563-584.	5.0	5
11	Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. Cell Chemical Biology, 2021, 28, 1446-1459.e6.	5.2	8
12	An affinity prediction approach for the ligand of E3 ligase Cbl-b and an insight into substrate binding pattern. Bioorganic and Medicinal Chemistry, 2021, 38, 116130.	3.0	1
13	Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications. Free Radical Biology and Medicine, 2021, 168, 129-141.	2.9	74
14	Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5â€“Mixed Lineage Leukemia 1 Proteinâ€“Protein Interaction for the Treatment of MLL Fusion Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8221-8245.	6.4	22
15	Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer. Journal of Medicinal Chemistry, 2021, 64, 8916-8938.	6.4	14
16	Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2021, 64, 10537-10556.	6.4	25
17	Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid Cell Leukemia 1 Inhibitors with High Affinity, Selectivity, and Oral Bioavailability. Journal of Medicinal Chemistry, 2021, 64, 11330-11353.	6.4	5
18	Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy. European Journal of Medicinal Chemistry, 2021, 220, 113539.	5.5	22

#	Article	IF	Citations
19	Application of cation-Ï€ interactions in enzyme-substrate binding: Design, synthesis, biological evaluation, and molecular dynamics insights of novel hydrophilic substrates for NQO1. European Journal of Medicinal Chemistry, 2021, 221, 113515.	5.5	5
20	Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with inÂvivo antitumor activity. European Journal of Medicinal Chemistry, 2021, 223, 113677.	5.5	10
21	Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects. European Journal of Medicinal Chemistry, 2021, 223, 113604.	5.5	5
22	An updated patent review of anticancer Hsp90 inhibitors (2013-present). Expert Opinion on Therapeutic Patents, 2021, 31, 67-80.	5.0	27
23	Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. Journal of Medicinal Chemistry, 2020, 63, 1798-1822.	6.4	117
24	Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present). Expert Opinion on Therapeutic Patents, 2020, 30, 209-225.	5.0	31
25	Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2020, 63, 3785-3816.	6.4	85
26	Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction. European Journal of Medicinal Chemistry, 2020, 188, 112027.	5.5	9
27	Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions. European Journal of Medicinal Chemistry, 2020, 207, 112734.	5.5	21
28	Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile. ACS Medicinal Chemistry Letters, 2020, 11, 2182-2189.	2.8	6
29	Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy. Drug Discovery Today, 2020, 25, 1873-1882.	6.4	10
30	Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Journal of Medicinal Chemistry, 2020, 63, 10045-10060.	6.4	16
31	Design, Synthesis, and Structureâ€“Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Proteinâ€“Protein Interaction Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 11149-11168.	6.4	30
32	A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions. Redox Biology, 2020, 34, 101565.	9.0	23
33	p62 as a therapeutic target for tumor. European Journal of Medicinal Chemistry, 2020, 193, 112231.	5.5	37
34	Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown. Journal of Medicinal Chemistry, 2020, 63, 4644-4654.	6.4	102
35	Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery. Acta Pharmaceutica Sinica B, 2020, 10, 1904-1925.	12.0	19
36	Discovery and Optimization of Small Molecules Targeting the Proteinâ€“Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. Journal of Medicinal Chemistry, 2020, 63, 1281-1297.	6.4	24

#	Article	IF	Citations
37	Recent developments of small molecules targeting RNA m6A modulators. European Journal of Medicinal Chemistry, 2020, 196, 112325.	5.5	17
38	Synthesis, sciatic nerve block activity evaluation and molecular docking of fluoro-substituted lidocaine analogs as local anesthetic agents. Medicinal Chemistry Research, 2019, 28, 1783-1795.	2.4	4
39	Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors. Bioorganic Chemistry, 2019, 91, 103181.	4.1	19
40	HSP90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer. Heat Shock Proteins, 2019, , 397-429.	0.2	1
41	CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-ÎºB activation. Redox Biology, 2019, 26, 101266.	9.0	93
42	Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1â€“Nrf2) Proteinâ€“Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity. Journal of Medicinal Chemistry, 2019, 62, 6796-6813.	6.4	29
43	Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer. Science Advances, 2019, 5, eaax2277.	10.3	57
44	Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications. Journal of Medicinal Chemistry, 2019, 62, 5725-5749.	6.4	41
45	Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light. Journal of Medicinal Chemistry, 2019, 62, 7583-7588.	6.4	10
46	Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy. Journal of Medicinal Chemistry, 2019, 62, 3840-3856.	6.4	32
47	Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective. European Journal of Medicinal Chemistry, 2019, 165, 172-197.	5.5	25
48	5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress. Free Radical Biology and Medicine, 2019, 134, 288-303.	2.9	54
49	Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway. European Journal of Medicinal Chemistry, 2018, 146, 251-259.	5.5	186
50	Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1138-1142.	2.2	14
51	Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy. Bioorganic and Medicinal Chemistry, 2018, 26, 356-365.	3.0	12
52	Synthesis, biological evaluation, and molecular docking of ropivacaine analogs as local anesthetic agents. Medicinal Chemistry Research, 2018, 27, 954-965.	2.4	4
53	Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERÎ±/VEGFR-2 ligands with anti-breast cancer activity. European Journal of Medicinal Chemistry, 2018, 150, 783-795.	5.5	33
54	Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency. European Journal of Medicinal Chemistry, 2018, 143, 1578-1589.	5.5	55

#	Article	IF	Citations
55	Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5. Bioorganic Chemistry, 2018, 76, 380-385.	4.1	8
56	Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2018, 61, 11280-11297.	6.4	33
57	Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. Journal of Medicinal Chemistry, 2018, 61, 9513-9533.	6.4	33
58	Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3726-3730.	2.2	12
59	Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury. European Journal of Medicinal Chemistry, 2018, 157, 1376-1394.	5.5	23
60	An NAD(P)H:Quinone Oxidoreductase 1 Responsive and Self-Immolative Prodrug of 5-Fluorouracil for Safe and Effective Cancer Therapy. Organic Letters, 2018, 20, 3635-3638.	4.6	25
61	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. Journal of Medicinal Chemistry, 2018, 61, 5332-5349.	6.4	35
62	3-(1H-Benzo[d]imidazol-6-yl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	4.0	11
63	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3. Molecules, 2018, 23, 1596.	3.8	1
64	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3KÎ´. Bioorganic and Medicinal Chemistry, 2018, 26, 4537-4543.	3.0	16
65	Lipid reducing activity of novel cholic acid (CA) analogs: Design, synthesis and preliminary mechanism study. Bioorganic Chemistry, 2018, 80, 396-407.	4.1	3
66	Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2879-2884.	2.2	7
67	Recent Advances in the Discovery of HIF-1Î±-p300/CBP Inhibitors as Anti-Cancer Agents. Mini-Reviews in Medicinal Chemistry, 2018, 18, 296-309.	2.4	23
68	Synthesis and evaluation of N -(benzofuran-5-yl)aromaticsulfonamide derivatives as novel HIF-1 inhibitors that possess anti-angiogenic potential. Bioorganic and Medicinal Chemistry, 2017, 25, 1737-1746.	3.0	14
69	Design, synthesis and biological evaluation of novel 3-substituted 4-anilino-coumarin derivatives as antitumor agents. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 867-874.	2.2	33
70	Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile. European Journal of Medicinal Chemistry, 2017, 129, 27-40.	5.5	37
71	Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction. European Journal of Medicinal Chemistry, 2017, 136, 63-73.	5.5	36
72	2-Substituted 3,7,8-trimethylnaphtho[1,2- b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. European Journal of Medicinal Chemistry, 2017, 138, 616-629.	5.5	22

#	Article	IF	Citations
73	Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3891-3899.	3.0	7
74	Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1Î± pathway. European Journal of Medicinal Chemistry, 2017, 137, 45-62.	5.5	37
75	Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5Î±-reductase type 1 and 2. Steroids, 2017, 124, 29-34.	1.8	9
76	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5Î±-androst-17Î²-amide derivatives as dual 5Î±-reductase inhibitors and androgen receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4212-4217.	2.2	3
77	Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90ÂC-terminal inhibitors. European Journal of Medicinal Chemistry, 2017, 141, 1-14.	5.5	17
78	Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents. European Journal of Medicinal Chemistry, 2017, 139, 390-400.	5.5	7
79	Prodrug strategy for cancer cell-specific targeting: A recent overview. European Journal of Medicinal Chemistry, 2017, 139, 542-563.	5.5	95
80	Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators. Bioorganic and Medicinal Chemistry, 2017, 25, 233-240.	3.0	16
81	Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function. Current Drug Targets, 2017, 18, 1572-1585.	2.1	15
82	Current Development of ROS-Modulating Agents as Novel Antitumor Therapy. Current Cancer Drug Targets, 2017, 17, 122-136.	1.6	36
83	Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments. Molecules, 2016, 21, 879.	3.8	7
84	The Keap1â€“Nrf2â€“ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Medicinal Research Reviews, 2016, 36, 924-963.	10.5	562
85	Polar Recognition Group Study of Keap1-Nrf2 Proteinâ€–Protein Interaction Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 835-840.	2.8	31
86	Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERÎ± and VEGFR-2 as anti-breast cancer agents. European Journal of Medicinal Chemistry, 2016, 118, 328-339.	5.5	27
87	Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. European Journal of Medicinal Chemistry, 2016, 118, 1-8.	5.5	38
88	Betulinic acid acetate, an antiproliferative natural product, suppresses client proteins of heat shock protein pathways through a CDC37-binding mechanism. RSC Advances, 2016, 6, 42537-42544.	3.6	2
89	High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. European Journal of Medicinal Chemistry, 2016, 124, 480-489.	5.5	41
90	Optimization and biological evaluation of celastrol derivatives as Hsp90â€“Cdc37 interaction disruptors with improved druglike properties. Bioorganic and Medicinal Chemistry, 2016, 24, 5431-5439.	3.0	39

#	Article	IF	Citations
91	Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification. Bioorganic and Medicinal Chemistry, 2016, 24, 6102-6108.	3.0	24
92	Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)â€“WDR5 interaction. Bioorganic and Medicinal Chemistry, 2016, 24, 6109-6118.	3.0	22
93	Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Proteinâ€“Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions. Journal of Medicinal Chemistry, 2016, 59, 10837-10858.	6.4	88
94	Structureâ€“activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity. Bioorganic and Medicinal Chemistry, 2016, 24, 4626-4635.	3.0	12
95	Design, Synthesis, and Initial Evaluation of Affinity-Based Small-Molecule Probes for Fluorescent Visualization and Specific Detection of Keap1. Journal of Medicinal Chemistry, 2016, 59, 7305-7310.	6.4	16
96	Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90. Journal of Medicinal Chemistry, 2016, 59, 10498-10519.	6.4	32
97	An inhibitor of the Keap1-Nrf2 protein-protein interaction protects NCM460 colonic cells and alleviates experimental colitis. Scientific Reports, 2016, 6, 26585.	3.3	82
98	Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy. MedChemComm, 2016, 7, 1271-1284.	3.4	11
99	Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core. Bioorganic and Medicinal Chemistry, 2016, 24, 3540-3547.	3.0	19
100	Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation. Bioorganic and Medicinal Chemistry, 2016, 24, 1006-1013.	3.0	25
101	A systematic molecular dynamics approach to the study of peptide Keap1â€“Nrf2 proteinâ€“protein interaction inhibitors and its application to p62 peptides. Molecular BioSystems, 2016, 12, 1378-1387.	2.9	29
102	3-(2-Oxo-2-phenylethylidene)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one (compound 1), a novel potent Nrf2/ARE inducer, protects against DSS-induced colitis via inhibiting NLRP3 inflammasome. Biochemical Pharmacology, 2016, 101, 71-86.	4.4	50
103	Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity. Current Topics in Medicinal Chemistry, 2016, 16, 1843-1854.	2.1	9
104	Synthesis and Biological Evaluation of Novel Oxazolo[5,4â€“d]pyrimidines as Potent VEGFRâ€2 Inhibitors. Chemistry and Biodiversity, 2015, 12, 528-537.	2.1	11
105	Discovery of NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with novel chemical scaffolds by shape-based virtual screening combined with cascade docking. RSC Advances, 2015, 5, 49471-49479.	3.6	8
106	Synthesis and evaluation of (Â±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1244-1248.	2.2	35
107	Discovery and identification of Cdc37-derived peptides targeting the Hsp90â€“Cdc37 proteinâ€“protein interaction. RSC Advances, 2015, 5, 96138-96145.	3.6	20
108	Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structureâ€“Activity Relationship Study. Journal of Medicinal Chemistry, 2015, 58, 5419-5436.	6.4	48

#	Article	IF	Citations
109	An improved and scalable synthesis of N-(5-(4-cyanophenyl)-3-hydroxypicolinoyl)glycine, a promising PHD2 inhibitor for the treatment of anemia. Tetrahedron Letters, 2015, 56, 5017-5019.	1.4	5
110	Synthesis and biological evaluation of isoflavone amide derivatives with antihyperlipidemic and preadipocyte antiproliferative activities. Bioorganic and Medicinal Chemistry, 2015, 23, 4428-4433.	3.0	3
111	Binding thermodynamics and kinetics guided optimization of potent Keap1â€“Nrf2 peptide inhibitors. RSC Advances, 2015, 5, 85983-85987.	3.6	43
112	Structureâ€“Activity and Structureâ€“Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1â€“Nrf2 Proteinâ€“Protein Interaction Inhibitor. Journal of Medicinal Chemistry, 2015, 58, 6410-6421.	6.4	76
113	Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: Introduction of an additional carboxyl group at the C-2 position of quinoline. European Journal of Medicinal Chemistry, 2015, 105, 145-155.	5.5	18
114	Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 1236-1240.	2.8	22
115	Novel approach to stereoselective synthesis of (E)/(Z)-(N-acyl-oxazolidinone)-eneglycinates. Research on Chemical Intermediates, 2015, 41, 749-760.	2.7	2
116	Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein. Mini-Reviews in Medicinal Chemistry, 2015, 15, 553-581.	2.4	0
117	Wogonin Suppresses Melanoma Cell B16-F10 Invasion and Migration by Inhibiting Ras-Medicated Pathways. PLoS ONE, 2014, 9, e106458.	2.5	30
118	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. European Journal of Medicinal Chemistry, 2014, 79, 399-412.	5.5	36
119	2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1). European Journal of Medicinal Chemistry, 2014, 82, 56-67.	5.5	46
120	Wogonin inhibits H2O2-induced angiogenesis via suppressing PI3K/Akt/NF-ÎºB signaling pathway. Vascular Pharmacology, 2014, 60, 110-119.	2.1	36
121	Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIFâ€1Î± and glycolysis, by inhibiting PI3K/Akt signaling pathway. Molecular Carcinogenesis, 2014, 53, E107-18.	2.7	87
122	Novel proteinâ€“protein interaction inhibitor of Nrf2â€“Keap1 discovered by structure-based virtual screening. MedChemComm, 2014, 5, 93-98.	3.4	55
123	Investigation of the intermolecular recognition mechanism between the E3 ubiquitin ligase Keap1 and substrate based on multiple substrates analysis. Journal of Computer-Aided Molecular Design, 2014, 28, 1233-1245.	2.9	25
124	Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochemical Pharmacology, 2014, 92, 220-234.	4.4	76
125	Highly Stereoselective Nucleophilic Addition of Difluoromethylâ€2â€pyridyl Sulfone to Sugar Lactones and Efficient Synthesis of Fluorinated 2â€Ketoses. European Journal of Organic Chemistry, 2014, 2014, 6150-6154.	2.4	16
126	Antiarrhythmic efficacy of CPUY102122, a multiple ion channel blocker, on rabbits with ischemia/reperfusion injury. Pharmacological Reports, 2014, 66, 1022-1030.	3.3	4

#	Article	IF	Citations
127	Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERÎ± and VEGFR-2. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2129-2133.	2.2	28
128	Discovery of Potent Keap1â€“Nrf2 Proteinâ€“Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis. Journal of Medicinal Chemistry, 2014, 57, 2736-2745.	6.4	193
129	Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-ÎºB signaling. European Journal of Pharmacology, 2014, 737, 57-69.	3.5	49
130	1,2-trans-1-Dihydroxyboryl benzyl S-glycoside as glycosyl donor. Carbohydrate Research, 2014, 398, 45-49.	2.3	8
131	Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. Oncotarget, 2014, 5, 8188-8201.	1.8	34
132	Drug resistance associates with activation of Nrf2 in <scp>MCF</scp>â€7/<scp>DOX</scp> cells, and wogonin reverses it by downâ€regulating Nrf2â€mediated cellular defense response. Molecular Carcinogenesis, 2013, 52, 824-834.	2.7	88
133	Garcinia Xanthones as Orally Active Antitumor Agents. Journal of Medicinal Chemistry, 2013, 56, 276-292.	6.4	55
134	Synthesis and bioevaluation of a series of Î±-pyrone derivatives asÂpotent activators of Nrf2/ARE pathway (part I). European Journal of Medicinal Chemistry, 2013, 66, 364-371.	5.5	27
135	Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 6466-6476.	3.0	23
136	De novo design of novel DNAâ€“gyrase inhibitors based on 2D molecular fingerprints. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4166-4171.	2.2	5
137	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). Bioorganic and Medicinal Chemistry, 2013, 21, 5339-5354.	3.0	20
138	3-Aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-ones as Potent Nrf2/ARE Inducers in Human Cancer Cells and AOM-DSS Treated Mice. Journal of Medicinal Chemistry, 2013, 56, 7925-7938.	6.4	40
139	Kinesin spindle protein inhibitors in cancer: a patent review (2008 â€“ present). Expert Opinion on Therapeutic Patents, 2013, 23, 1547-1560.	5.0	13
140	Wogonin induced cytotoxicity in human hepatocellular carcinoma cells by activation of unfolded protein response and inactivation of <scp>AKT</scp>. Hepatology Research, 2013, 43, 890-905.	3.4	34
141	Design and discovery of 4-anilinoquinazoline ureas as multikinase inhibitors targeting BRAF, VEGFR-2 and EGFR. MedChemComm, 2013, 4, 979.	3.4	24
142	Synthesis and Evaluation of Gambogic Acid Derivatives as Antitumor Agents. Part III. Chemistry and Biodiversity, 2013, 10, 73-85.	2.1	14
143	Antiarrhythmic Efficacy of <scp>CPUY</scp>11018 Under Pathological Conditions. Drug Development Research, 2013, 74, 194-202.	2.9	1
144	A General and Facile Synthesis of Novel Polysubstituted Quinazolinâ€4(3H)â€ones. Journal of Heterocyclic Chemistry, 2013, 50, 169-174.	2.6	1

#	Article	IF	Citations
145	Microwave-Assisted Efficient and Green Synthesis of Hydroxyxanthone in Water. Synthetic Communications, 2012, 42, 2952-2958.	2.1	11
146	Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochemistry and Cell Biology, 2012, 90, 718-730.	2.0	56
147	Studies on Chemical Structure Modification and Structureï£¿Activity Relationship of Derivatives of Gambogic Acid at C(39). Chemistry and Biodiversity, 2012, 9, 1579-1590.	2.1	12
148	Wogonin Induced Calreticulin/Annexin A1 Exposure Dictates the Immunogenicity of Cancer Cells in a PERK/AKT Dependent Manner. PLoS ONE, 2012, 7, e50811.	2.5	59
149	The Multiple Ion Channel Blocker CPUY11018 Prevents Aconitine-Induced Arrhythmias. Drug Development Research, 2012, 73, 214-221.	2.9	4
150	Synthesis and Antiâ€tumor Evaluation of Novel Câ€37 Modified Derivatives of Gambogic Acid. Chinese Journal of Chemistry, 2012, 30, 1083-1091.	4.9	9
151	Novel Dualâ€Siteâ€Binding Neuraminidase Inhibitor from Virtual Screening by Pharmacophore and Molecular Dynamics Methods. Chinese Journal of Chemistry, 2012, 30, 1735-1740.	4.9	3
152	Studies on gambogic acid (IV): Exploring structureâ€“activity relationship with ÎºB kinase-beta (IKKÎ²). European Journal of Medicinal Chemistry, 2012, 51, 110-123.	5.5	21
153	Facile synthesis of 2,5,7-trisubstituted oxazolo[5,4-d]pyrimidines via copper-catalyzed intramolecular Câ€“O bond formation. Tetrahedron, 2012, 68, 4248-4251.	1.9	15
154	Synthesis and Antiâ€tumor Evaluation of Bâ€ring Modified Caged Xanthone Analogues of Gambogic Acid. Chinese Journal of Chemistry, 2012, 30, 35-42.	4.9	8
155	Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. Journal of Molecular Modeling, 2012, 18, 1023-1036.	1.8	34
156	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening. Acta Pharmaceutica Sinica B, 2011, 1, 240-247.	12.0	15
157	CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity. Journal of Pharmacy and Pharmacology, 2011, 63, 1462-1469.	2.4	9
158	Developmental toxicity and genotoxicity studies of wogonin. Regulatory Toxicology and Pharmacology, 2011, 60, 212-217.	2.7	19
159	Total synthesis of aldehyde-containing Garcinia natural products isomorellin and gaudichaudione A. Tetrahedron, 2011, 67, 4774-4779.	1.9	13
160	Structureâ€Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors. Molecular Informatics, 2011, 30, 579-592.	2.5	9
161	Pharmacophore Modeling and in Silico Screening Studies to Design Potential KDR Kinase Inhibitors. Chinese Journal of Chemistry, 2011, 29, 1107-1113.	4.9	0
162	Potassium Channel Blockers as Antiarrhythmic Agents. , 2011, , 117-147.		0

#	Article	IF	Citations
163	Comparison of Electron Captureâ€"Atmospheric Pressure Chemical Ionization and Electrospray Ionization for the Analysis of Gambogic Acid and its Main Circulating Metabolite in Dog Plasma. European Journal of Mass Spectrometry, 2010, 16, 605-617.	1.0	4
164	Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. Journal of Pharmacy and Pharmacology, 2010, 60, 1459-1463.	2.4	17
165	Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents. European Journal of Medicinal Chemistry, 2010, 45, 4343-4353.	5.5	24
166	In silico binding characteristics between human histamine H1 receptor and antagonists. Journal of Molecular Modeling, 2010, 16, 1529-1537.	1.8	5
167	Structureâ€Based Virtual Screening and Electrophysiological Evaluation of New Chemotypes of K_v1.5 Channel Blockers. ChemMedChem, 2010, 5, 1353-1358.	3.2	8
168	Effects of a novel class III antiarrhythmic agent, CPUY11018, on rat atrial fibrillation. Drug Development Research, 2010, 71, 303-312.	2.9	7
169	Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism. Toxicology Letters, 2010, 197, 201-210.	0.8	58
170	Convenient Synthesis of Wogonin, A Flavonoid Natural Product with Extensive Pharmacological Activity. Organic Preparations and Procedures International, 2009, 41, 327-330.	1.3	14
171	Research Toward Potassium Channels on Tumor Progression. Current Topics in Medicinal Chemistry, 2009, 9, 322-329.	2.1	15
172	The Interactions Between hERG Potassium Channel and Blockers. Current Topics in Medicinal Chemistry, 2009, 9, 330-338.	2.1	18
173	Pharmacophore Identification of Hydroxamate HDAC 1 Inhibitors. Chinese Journal of Chemistry, 2009, 27, 557-564.	4.9	10
174	Synthesis and pHâ€induced phase transition behavior of PAA/PVA nanogels in aqueous media. Journal of Applied Polymer Science, 2009, 111, 358-362.	2.6	21
175	Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology, 2009, 256, 135-140.	4.2	41
176	Toxicological studies of wogonin in experimental animals. Phytotherapy Research, 2009, 23, 417-422.	5.8	37
177	Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers. QSAR and Combinatorial Science, 2009, 28, 59-71.	1.4	12
178	Pharmacophore Guided 3Dâ€QSAR CoMFA Analysis of Amino Substituted Nitrogen Heterocycle Ureas as KDR Inhibitors. QSAR and Combinatorial Science, 2009, 28, 1524-1536.	1.4	4
179	Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology, 2009, 260, 60-67.	4.2	81
180	Studies on chemical structure modification and biology of a natural product, Gambogic acid (I): Synthesis and biological evaluation of oxidized analogues of gambogic acid. European Journal of Medicinal Chemistry, 2009, 44, 2611-2620.	5.5	41

#	Article	IF	Citations
181	Molecular hybridization, synthesis, and biological evaluation of novel chroman IKr and IKs dual blockers. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1477-1480.	2.2	11
182	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6284-6288.	2.2	12
183	One-Pot Synthesis of Tetrahydrobenzo[b]pyran Derivatives Catalyzed by Amines in Aqueous Media. Organic Preparations and Procedures International, 2009, 41, 77-82.	1.3	32
184	Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs. Journal of Ethnopharmacology, 2009, 124, 257-262.	4.1	32
185	Discovery of a Novel Series of Quinolone and Naphthyridine Derivatives as Potential Topoisomerase I Inhibitors by Scaffold Modification. Journal of Medicinal Chemistry, 2009, 52, 5649-5661.	6.4	66
186	Microwave-Assisted Simple Synthesis of Substituted 4-Quinolone Derivatives. Synthetic Communications, 2009, 39, 4375-4383.	2.1	14
187	Design, Synthesis and Evaluation of Tetrahydroisoquinolines as New Kinesin Spindle Protein Inhibitors. Chemical and Pharmaceutical Bulletin, 2009, 57, 567-571.	1.3	8
188	Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. Journal of Molecular Medicine, 2008, 86, 1367-1377.	3.9	56
189	Cascade Reaction and Synthesis of Bicyclo[2,2,2]octenones. Chinese Journal of Chemistry, 2008, 26, 363-367.	4.9	4
190	A Pharmacophore Modeling Study of Drugs Inducing Cardiotoxic Side Effects. Chinese Journal of Chemistry, 2008, 26, 2125-2132.	4.9	2
191	Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. Journal of Molecular Graphics and Modelling, 2008, 26, 1160-1168.	2.4	60
192	Modeling the binding modes of Kv1.5 potassium channel and blockers. Journal of Molecular Graphics and Modelling, 2008, 27, 178-187.	2.4	22
193	Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochemistry and Cell Biology, 2008, 86, 386-395.	2.0	50
194	Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up-regulates phospholipid scramblase 1 gene expression. Cancer Science, 2008, 99, 689-695.	3.9	40
195	Inhibition of glioblastoma growth and angiogenesis by gambogic acid: An in vitro and in vivo study. Biochemical Pharmacology, 2008, 75, 1083-1092.	4.4	77
196	Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCÎ´ phosphorylation. European Journal of Pharmacology, 2008, 591, 7-12.	3.5	50
197	Structure-activity Relationship of Gambogic Acid. Chinese Journal of Natural Medicines, 2008, 6, 37-42.	1.3	2
198	Studies on the toxicity of gambogic acid in rats. Journal of Ethnopharmacology, 2008, 117, 433-438.	4.1	73

#	Article	IF	Citations
199	Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells. Cancer Letters, 2008, 262, 223-231.	7.2	48
200	Microwave-Assisted Esterification of Diverse Carboxylic Acids and Chiral Amino Acids. Synthetic Communications, 2008, 38, 4107-4115.	2.1	13
201	Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Molecular Cancer Therapeutics, 2008, 7, 3298-3305.	4.1	84
202	Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors. Molecular Cancer Therapeutics, 2008, 7, 1007-1012.	4.1	27
203	Strategies for atrial fibrillation therapy: focusing onI_{Kur}potassium channel. Expert Opinion on Therapeutic Patents, 2007, 17, 1443-1456.	5.0	13
204	A novel structure-based virtual screening model for the hERG channel blockers. Biochemical and Biophysical Research Communications, 2007, 355, 889-894.	2.1	55
205	Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Letters, 2007, 256, 259-266.	7.2	133
206	Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Letters, 2007, 258, 80-89.	7.2	95
207	Pharmacophore identification of KSP inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 722-726.	2.2	26
208	Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Research, 2007, 74, 16-24.	4.1	158
209	Docking studies on kinesin spindle protein inhibitors: an important cooperative â€˜minor binding pocketâ€™ which increases the binding affinity significantly. Journal of Molecular Modeling, 2007, 13, 987-992.	1.8	18
210	A Facile and Scaleable Synthesis of 3-O-Decladinose-6-methyl-10,11-dehydrate-erythromycin-3-one-2â€˜-acetate, an Important Intermediate for Ketolide Synthesis. Organic Process Research and Development, 2006, 10, 446-449.	2.7	13
211	Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochemical and Biophysical Research Communications, 2006, 351, 521-527.	2.1	79
212	Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sciences, 2006, 78, 1238-1245.	4.3	99
213	The Anticancer Activities of Wogonin in Murine Sarcoma S180 both in Vitro and in Vivo. Biological and Pharmaceutical Bulletin, 2006, 29, 1132-1137.	1.4	62
214	The First Total Synthesis of the Diastereoisomers A and B ofTuxpanolidefromPerymenium hintonii. Journal of the Chinese Chemical Society, 2006, 53, 349-358.	1.4	1
215	Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721. Anti-Cancer Drugs, 2006, 17, 797-805.	1.4	55
216	Toxicological Studies of Gambogic Acid and its Potential Targets in Experimental Animals. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 178-184.	2.5	57

#	Article	IF	Citations
217	Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer Chemotherapy and Pharmacology, 2006, 58, 434-443.	2.3	69
218	CONVENIENT AND RAPID PREPARATION OF INDENE DIMERS FROM INDENES OR INDANOLS. Organic Preparations and Procedures International, 2006, 38, 490-494.	1.3	0
219	Kinesin spindle protein Inhibitors as anticancer agents. Expert Opinion on Therapeutic Patents, 2006, 16, 1517-1532.	5.0	21
220	An efficient synthesis of an optically active (-)-(3R, 4R,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td (5R)-4-(1-hydroxyl-isopropyl)-3-acet 665-668.	1.3	2
221	Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Biochemical and Biophysical Research Communications, 2005, 332, 677-687.	2.1	22
222	The pharmacophore hypotheses of IKr potassium channel blockers: novel class III antiarrhythmic agents. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4771-4777.	2.2	46
223	Gambogic Acid Inhibits Proliferation of Human Lung Carcinoma SPC-A1 Cells in Vivo and in Vitro and Represses Telomerase Activity and Telomerase Reverse Transcriptase mRNA Expression in the Cells. Biological and Pharmaceutical Bulletin, 2004, 27, 1769-1774.	1.4	174
224	Gambogic Acid Induces Apoptosis and Regulates Expressions of Bax and Bcl-2 Protein in Human Gastric Carcinoma MGC-803 Cells. Biological and Pharmaceutical Bulletin, 2004, 27, 998-1003.	1.4	176
225	General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacologica Sinica, 2004, 25, 769-74.	6.1	90
226	USE OF POLYPHOSPHORIC ACID IN THE HYDROLYSIS OF CHROMONE ESTERS. Synthetic Communications, 2002, 32, 709-714.	2.1	4
227	PREPARATION OF N-UNSUBSTITUTED THIOAMIDES BY A MODIFIED WILLGERODT-KINDLER REACTION. Organic Preparations and Procedures International, 1991, 23, 435-438.	1.3	11